GLP-1 market seen topping $133.9 billion by 2034

By AI, Created 1:01 PM UTC, May 19, 2026, /AGP/ – Polaris Market Research says the GLP-1 drug market will grow from $58.48 billion in 2026 to $133.92 billion by 2034 as semaglutide, tirzepatide and newer oral and next-gen therapies expand use beyond diabetes. The report points to supply shortages, reimbursement battles and new cardiovascular and kidney uses as key forces shaping the market.

Why it matters: - GLP-1 drugs are moving from a niche diabetes category into a broader obesity, cardiovascular and metabolic disease market. - The shift could reshape prescribing, payer coverage and pharma competition over the next decade. - Polaris Market Research projects the market will nearly double by 2034, reaching $133.92 billion from $58.48 billion in 2026, a 10.90% CAGR.

What happened: - Polaris Market Research released a new GLP-1 Market report on May 19, 2026. - The report says demand for glucagon-like peptide-1 drugs is rising quickly across diabetes and obesity care. - Semaglutide and tirzepatide are leading the category. - The report names Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound as key products. - The report also points to next-generation receptor agonists in development.

The details: - GLP-1 receptor agonists started as type 2 diabetes treatments. - Weight-loss results and heart benefits widened use beyond endocrinology. - The report lists semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide and pipeline molecules by drug type. - Covered indications include type 2 diabetes, obesity and weight management, cardiovascular risk reduction, NASH, CKD and Alzheimer’s. - Delivery formats include injectable and oral drugs. - The report includes hospitals, retail pharmacies, online pharmacies, prescription sales and direct-to-consumer telehealth platforms in its market view. - More than 40% of U.S. adults are classified as obese, which is helping drive broader use. - The AHA and ADA now recommend GLP-1 drugs as first-line therapy, according to the report. - Ozempic and Wegovy generate more than $21 billion a year for Novo Nordisk. - Demand continues to outpace supply, and shortages are expected to continue through 2025. - Tirzepatide’s Mounjaro and Zepbound are showing stronger weight-loss trial results. - Oral GLP-1 drugs, including Rybelsus, are expanding access for patients who prefer to avoid injections. - FDA shortage designations are enabling compounded semaglutide, leaving the issue in a regulatory gray zone. - Medicare coverage debates, employer plan pressure and PBM negotiations remain major access and pricing gatekeepers.

Between the lines: - The market story is no longer just about diabetes control; it is about a platform therapy with uses that could stretch across multiple chronic diseases. - Cardiovascular, kidney and neurological trials could create new revenue pools if clinical benefits continue to hold up. - SELECT showed semaglutide reduced major cardiovascular events by 20%. - FLOW trial data suggests GLP-1 drugs may help protect kidney function. - Early work in Parkinson’s, Alzheimer’s and addiction remains preliminary, but even modest results could broaden the addressable market. - Triple agonists such as retatrutide are in Phase 3, signaling a next wave of competition. - Novo Nordisk and Eli Lilly remain the clear leaders, but the field is widening. - Novo Nordisk is investing more than $6 billion to expand manufacturing capacity and has CagriSema in Phase 3. - Eli Lilly’s tirzepatide remains a growth engine, and oral non-peptide orforglipron is also in Phase 3. - Amgen, Pfizer, Roche, AstraZeneca and Viking Therapeutics are advancing obesity programs. - Semaglutide patents are expected to expire in the mid-2030s, opening the door to biosimilars from Teva, Sandoz and Indian generic makers. - Big pharma is also buying obesity-focused platforms, including devices and digital tools, to strengthen its position.

What’s next: - The report expects broader use of GLP-1 drugs as access improves and more oral or next-gen options reach patients. - North America is projected to keep the largest revenue share, while Asia-Pacific is the fastest-growing region. - Europe remains an important market, led by Germany, the UK and France. - Latin America and the Middle East and Africa are earlier-stage opportunities tied to urbanization and rising metabolic disease. - The report says investors, payers and healthcare systems will keep watching reimbursement, manufacturing scale and patent timelines as the next major market drivers.

The bottom line: - GLP-1 drugs have moved from diabetes care into one of pharma’s most important growth markets, and the next battle will be won on access, supply and expansion into new diseases.